2013年8月《肿瘤学年鉴》发表《早期乳腺癌个体化治疗：2013年St Gallen会议早期乳腺癌初始治疗专家共识》，重点包括：多基因序列分析领域已经成熟，倾向用基因分析结果取代过去免疫组化替代分型以制定luminal型病人的基础化疗方案；细化无HER2过表达luminal型早期分类和适宜处理原则；支持减少腋窝清扫的必要性；以及缩短放疗周期合理性等多项内容。其中以基因分析为依据的推荐意见，代表乳腺癌领域推动个体化治疗的重大理念变更。

Review for the St Gallen international expert consesus from 2003 to 2013        GAO Guo-xuan, XIN Ling, LIU Qian, et al. Breast Disease Certer, Peking University First Hospital, Beijing 100034, China
Corresponding author: LIU Yin-hua,E-mail：liuyinhua@medmail.com.cn
Abstract    In August 2013 Annals of Oncology， it published the 13th St Gallen Consensus on the Primary Therapy of Early Breast Cancer. Major issues that have been highlighted included: multi-gene molecular assays are readily available and there is a trend towards basing chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions; refining its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2(HER2) oncogene; supporting less extensive surgery to the axilla and shorter durations of radiation therapy. The recommendations based on the genomic analysis represented the significant alteration of major concepts of personalized treatment in the field of early breast cancer.